Truist Securities analyst Gregory Renza has reiterated a 'Buy' rating for Regeneron Pharmaceuticals and slightly increased its price target from $769 to $772. This indicates a continued positive outlook from the analyst, suggesting potential for modest upside for the stock.
Truist Securities analyst Gregory Renza maintained a 'Buy' rating on Regeneron Pharmaceuticals and raised the price target from $769 to $772. This action signals continued confidence in the company's performance and future prospects from a prominent financial institution. While the price target increase is modest, it reinforces a positive sentiment for REGN, potentially attracting investors looking for analyst-backed growth. For traders, this could lead to a slight positive short-term bump or reinforce existing long positions, but the small change in target suggests no major immediate catalyst. The key opportunity lies in the sustained 'Buy' rating, indicating a belief in long-term value.